Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 12, 2025
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
GlobeNewswire
·
May 12, 2025
BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful completion of the dose optimization of its …
Brain Cancer Canada Grants McGill University $100,000 to Advance Pediatric Brain Cancer Research
GlobeNewswire
·
May 12, 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to award a $100,000 pediatric research grant to Dr. Carl Ernst, professor and scientist at McGill University, and his team. The work explores a gene therapy treatment for pediatric …
A Decade of Dapper: Movember and the Distinguished Gentleman’s Ride Gear Up to Celebrate 10 Years of Riding Together for Men’s Health
GlobeNewswire
·
May 12, 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- A global movement with a decade of impact! This year, Movember and The Distinguished Gentleman’s Ride (DGR) proudly mark 10 years of partnership, riding to raise vital funds that lift the profile of men’s health …
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
GlobeNewswire
·
May 12, 2025
PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
GlobeNewswire
·
May 12, 2025
Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin for the treatment of R/R …
ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors
GlobeNewswire
·
May 12, 2025
Industry veteran brings over 30 years of experience driving technical, operational, and commercial excellence Has served as ElevateBio’s strategic advisor over the past year, working closely with the executive team to scale business and operations WALTHAM, …
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
GlobeNewswire
·
May 12, 2025
May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 …
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
GlobeNewswire
·
May 12, 2025
SARASOTA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced it will host a management update webinar on …
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
GlobeNewswire
·
May 12, 2025
Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a …
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
GlobeNewswire
·
May 12, 2025
CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today …
Registration for 2025 World Astatine Community Meeting Now Open
GlobeNewswire
·
May 12, 2025
NEW ORLEANS, May 12, 2025 (GLOBE NEWSWIRE) -- The first-ever U.S.-based meeting of the World Astatine Community will take place June 19-20, 2025 at the Sheraton in downtown New Orleans. The event will highlight public and private sector research and …
Collegium Announces $25 Million Accelerated Share Repurchase Program
GlobeNewswire
·
May 12, 2025
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it …
ABLi Therapeutics Launches with a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases
GlobeNewswire
·
May 12, 2025
Lead candidate Risvodetinib (ABLi-148009) is an oral, once-daily, potent, brain-penetrant, selective c-Abl kinase inhibitor that is the first to drive clearance of disease pathology in human Parkinson’s disease ABLi’s proprietary Re-engineering Approach …
Bioliberty Launches Lifehub Clinic to Transform Therapy through Soft Robotics and Gamified Exercises
GlobeNewswire
·
May 12, 2025
EDINBURGH, United Kingdom and BOSTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Bioliberty, a medtech startup transforming the delivery of physical and occupational therapy, today announced the launch of its first product, Lifehub Clinic at Rehab Week being …
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
GlobeNewswire
·
May 12, 2025
DSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025 SYDNEY, May 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “ …
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
GlobeNewswire
·
May 12, 2025
TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway …
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
GlobeNewswire
·
May 12, 2025
LEIDEN, Netherlands …
Foresight Diagnostics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 12, 2025
BOULDER, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”) a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, today announced that Jake Chabon, PhD, …
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
GlobeNewswire
·
May 12, 2025
RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other treatments for ophthalmic …
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference …